

sent by email:

cc.

Dr Pamela McHenry and colleagues
British Association of Dermatologists
Willan House
4 Fitzroy Square
London
W1T 5HQ

3 July 2018

Dear Dr McHenry and colleagues

Final Evaluation Determination: Afamelanotide for treating erythropoietic protoporphyria (EPP)

Thank you for your letter of 27 June.

I have reviewed my initial impression of your points 3, 6, 7, and 8 as you request. However for the reasons already given I still do not think they amount to valid appeal points.

The appeal panel will therefore consider your points 1, 4 and 5 at its meeting on 30 July.

Yours sincerely

Dr Rosie Benneworth
Vice Chair
National Institute for Health and Care Excellence

